duoset micb sandwich elisa kit  (R&D Systems)

Journal: Journal for Immunotherapy of Cancer

Article Title: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC + tumors respond to PD1/PD-L1 blockade therapy

doi: 10.1186/s40425-019-0693-y

Figure Lengend Snippet: Therapeutic efficacy of antibody cocktail composed of the sMIC-targeting antibody B10G5 and an anti-PD-L1 antibody in the autochthonous bi-transgenic TRAMP/MICB mice. a , Depiction of the therapy schema. Cohorts of 27 to 29-week-old TRAMP/MICB mice (male) were assigned to four therapy groups according to similar distribution of serum levels of sMIC for the four defined therapy. All therapies were given twice weekly for 8 weeks. b , Prostate organ weight, which reflects tumor weight in situ, of the animals at necropsy after receiving an 8-week duration of specific therapy. c , Incidence of lung metastasis in animals of each therapeutic group after a duration of 8-week therapy. Due to multiple focal micrometastasis in distant organs, quantitation of micrometastasis in each organ is not achievable. d , Kaplan-Meier survival at the designated study point (end of 8-week therapy). ns, not statistically significant

Article Snippet: Serum levels of sMICB from experimental mice were assessed using Duoset MICB Sandwich ELISA kit (Cat. DY1599) from R&D Systems according to manufacturer’s instruction.

Techniques: Drug discovery, Transgenic Assay, In Situ, Quantitation Assay

Journal: Journal for Immunotherapy of Cancer

Article Title: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC + tumors respond to PD1/PD-L1 blockade therapy

doi: 10.1186/s40425-019-0693-y

Figure Lengend Snippet: Anti-PD-L1 antibody in combination with sMIC-targeting mAb B10G5 cooperatively enhances antigen-specific CD8 T cell anti-tumor responses. a , Depiction of experiment schema. CFSE-labeled tumor antigen SV40TAg-specific TCR-I CD8 T cells were transferred into TRAMP/MICB mice that have received 4-week duration of therapy, which was continued post transfer of TCR-I CD8 T cells. Data shown are 14-day post-transfer of CFSE-labeled TCR-I CD8 T cells. b and c , Representative dot plots ( b ) and summary data ( c ) demonstrating the percentage of D b /I-tetramer + SV40TAg-specific CD8 T cells in dLN, tumor infiltrates, and spleen. d and e , Representative histograms ( d ) and summary data ( e ) demonstrating proliferation of SV40Tag-specific CD8 T cells represented by CFSE lo population. f and g , Representative histograms ( f ) and summary data ( g ) demonstrating the response of D b /I-tetramer + SV40TAg-specific CD8 T cells to ex vivo SV40TAg peptide re-stimulation as measured by IFNγ production

Article Snippet: Serum levels of sMICB from experimental mice were assessed using Duoset MICB Sandwich ELISA kit (Cat. DY1599) from R&D Systems according to manufacturer’s instruction.

Techniques: Labeling, Ex Vivo

Journal: Journal for Immunotherapy of Cancer

Article Title: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC + tumors respond to PD1/PD-L1 blockade therapy

doi: 10.1186/s40425-019-0693-y

Figure Lengend Snippet: Anti-sMIC therapy with B10G5 up-regulates PD-L1 expression on tumor cells, which is in part NK cell dependent. a , Depletion of NK cells (dpNK) during therapy diminishes the therapeutic effect of co-targeting sMIC and PD-L1 as assessed by prostate weight at necropsy. All treatments were given twice weekly i.p. for 8 weeks. b , Representative histograms from flow cytometry analyses demonstrating the percentage of PD-L1 + tumor cells from TRAMP/MICB mice. c , Summary data of the percentage of PD-L1 + tumor cells from ( a )

Article Snippet: Serum levels of sMICB from experimental mice were assessed using Duoset MICB Sandwich ELISA kit (Cat. DY1599) from R&D Systems according to manufacturer’s instruction.

Techniques: Expressing, Flow Cytometry